Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(6), 520-529 | ISSN:2251-6727

# Environmental Implications of Plant-Derived Nano Particle-Based Molecular Biomarkers in Cancer Staging and Therapy: A Comprehensive Review

**Richa Goel[1], J. Anburaj[2], Priyanka Soni[3], Neha P. Singh[4], Ramenani Hari Babu[5], Mohd Ruman Khan[6], Madhuben Sharma[7], Roma Ghai[1*]**

[1]KIET Group of Institutions (KIET School of Pharmacy), Muradnagar, Ghaziabad, Uttar Pradesh 201206, India
[2]Dept of Pharmaceutics, Arulmigu Kalasalingam College of Pharmacy, Krishnankoil -626126 Tamilnadu
[3]Faculty of Pharmacy, Mandsaur University, Mandsaur, India
[4]Dev Bhoomi Uttarakhand University, Dehradun
[5]MB School of Pharmaceutical Sciences, Mohan Babu University, Sree Sainath Nagar, Tirupati
[6]Rakshpal Bahadur college of Pharmacy, Bareilly, India
[7]Sustainability Cluster, School of Advanced Engineering, University of Petroleum and Energy Studies, Bidholi, Energy Acres, Dehradun, Uttarakhand 248007, India

***(Received: 07 October 2023 Revised: 12 November Accepted: 06 December)***

**KEYWORDS**
Nanoparticle Environmental Impact, Plant-Derived Biomarkers, Cancer Diagnosis, Therapeutic Nanosystems, Eco-friendly Nanoparticle Production, Sustainable Cancer Therapy

**ABSTRACT:**
Recent biomedical research has highlighted the promising potential of integrating plant-derived nanoparticles (NPs) as molecular biomarkers in both cancer staging and therapy. This comprehensive review aims to delve into the multifaceted landscape encompassing the use of these NPs in cancer diagnostics and treatment modalities. In the domain of cancer diagnostics, the distinctive physicochemical properties of plant-derived NPs make them highly effective in detecting and staging various cancer types. Their specificity and sensitivity enable precise identification of cancerous cells, revolutionizing early detection and enabling timely interventions. Plant-derived NPs extend their utility to cancer therapy by serving as carriers for therapeutic agents, facilitating targeted delivery to specific tumor sites while minimizing systemic toxicity. Their biocompatibility and potential for controlled drug release hold significant promise in enhancing treatment efficacy and patient outcomes. However, amidst these remarkable advancements in cancer research, it is crucial to critically assess the environmental implications associated with the widespread use of plant-derived NPs in healthcare settings. Concerns about their fate, behavior post-administration, and potential impact on ecosystems necessitate thorough investigation, particularly regarding bioaccumulation, persistence, and subsequent environmental effects. This review also addresses regulatory and ethical considerations intertwined with the utilization of plant-derived NPs in cancer care. The need for stringent regulatory frameworks and ethical guidelines becomes apparent to ensure the safe and responsible use of these innovative tools while mitigating potential environmental risks.

## Introduction

Cancer diagnosis and treatment stand at a pivotal stage, propelled by the transformative potential of molecular biomarkers[1]. Among these advancements, the integration of plant-derived nanoparticles (PDNPs) as molecular biomarkers in cancer staging and therapy marks a groundbreaking trajectory. This innovative paradigm shift promises unparalleled precision and efficacy in diagnosing and treating cancer[2]. However, as the scientific community embraces this evolution, a crucial facet demands profound exploration: the consequential environmental implications of these PDNP-based technologies[3]. The burgeoning reliance on PDNPs raises critical questions about their ecological footprint throughout their lifecycle – from synthesis and application to eventual disposal[5]. Understanding the intricate environmental impact of these nanosystems becomes paramount as we navigate the delicate balance between medical innovation and environmental stewardship[6]. This comprehensive review endeavors to

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(6), 520-529 | ISSN:2251-6727

navigate this nuanced terrain, delving into the multifaceted dimensions of PDNP-based molecular biomarkers in cancer care, aiming to unravel their ecological footprint, evaluate potential risks, and propose strategies to harmonize their biomedical benefits with environmental sustainability[7].

**PDNPs for Cancer Biomarkers**

Plant-Derived Nanoparticles (PDNPs) have emerged as a promising avenue in the development of cancer biomarkers, offering several advantages over traditional approaches. These advantages not only enhance the accuracy and efficacy of cancer diagnostics but also pave the way for innovative therapeutic interventions[8].

**Advantages Over Traditional Biomarker Approaches**

***Specificity and Sensitivity in Early Cancer Detection:*** PDNPs exhibit an exceptional capacity for precise and sensitive cancer detection, marking a significant advancement over conventional biomarker approaches[9,10]. Their unique physicochemical properties enable them to detect minute alterations in biomolecular profiles associated with cancer cells, allowing for early-stage detection[11]. This heightened sensitivity ensures that even subtle changes indicative of cancer initiation or progression are identified, empowering clinicians to intervene at earlier, more treatable stages[12].

***Multifunctionality for Theranostics (Diagnosis and Therapy)***: A distinguishing feature of PDNPs lies in their multifunctionality, enabling both diagnosis and therapy within a single platform—an approach known as theranostics[13]. These nanoparticles can encapsulate therapeutic agents while concurrently serving as imaging contrast agents. This dual capability enables targeted delivery of therapeutics to specific cancer sites while visualizing the tumor, optimizing treatment efficacy, and minimizing off-target effects[14].

***Biocompatibility and Degradability:*** PDNPs possess inherent biocompatibility and degradability owing to their natural origin, ensuring compatibility with biological systems and minimal toxicity concerns[15]. Their composition allows for gradual degradation and clearance from the body, reducing the risk of long-term adverse effects often associated with synthetic nanoparticles. This characteristic enhances their safety profile, making them a more viable option for clinical applications[16,17].

**Types of PDNPs Used for Cancer Biomarkers**

***Polysaccharides, Proteins, Lipids, and Combinations:*** PDNPs encompass a diverse array of materials derived from various plant sources, including polysaccharides, proteins, lipids, and their combinations[18]. Each material offers distinct properties that can be tailored to specific applications in cancer biomarker development[19]. For instance, polysaccharide-based PDNPs might provide excellent biocompatibility, while protein-derived nanoparticles could offer enhanced stability or targeting capabilities. Combinations of these materials further widen the spectrum of potential functionalities and applications in cancer diagnostics and therapy[20]. PDNPs have shown remarkable promise in the development of specific biomarkers tailored for various types of cancers, demonstrating their versatility and potential clinical applicability[21]. For instance, in prostate cancer, PDNPs derived from plant proteins have been engineered to target prostate-specific membrane antigen (PSMA), enabling highly specific imaging and therapy delivery to prostate cancer cells while minimizing collateral damage to healthy tissue[22]. In breast cancer, polysaccharide-based PDNPs functionalized with specific antibodies have exhibited an exceptional ability to recognize and bind to surface receptors overexpressed in breast cancer cells[23]. This targeted binding facilitates both early detection through imaging modalities and precise drug delivery for therapeutic interventions. Furthermore, in lung cancer, lipid-based PDNPs have been developed to encapsulate chemotherapeutic agents, enhancing their delivery specifically to lung tumor sites[24,25]. This approach not only improves the therapeutic efficacy but also minimizes systemic side effects associated with conventional chemotherapy[26].

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(6), 520-529 | ISSN:2251-6727



Figure 1. Biomarkers within the Cancer

**Environmental Implications of PDNP Production and Use**

***Plant Cultivation and Harvesting:*** The advent of plant-derived nanoparticles (PDNPs) has surged as a beacon of hope in medical science, particularly in cancer staging and therapy[27]. However, the burgeoning demand for these nanoparticles poses a significant challenge in terms of their environmental footprint, starting right from the cultivation and harvesting of the source plants[28]. The escalating demand for specific plant species, rich sources of nanoparticles, often results in intensive cultivation methods[29]. This leads to the employment of unsustainable agricultural practices, such as monoculture farming, where vast tracts of land are devoted solely to these plants[30]. Monoculture not only depletes soil nutrients rapidly but also heightens susceptibility to diseases and pests, necessitating increased pesticide and fertilizer use. Such practices, while meeting the PDNP demand, contribute significantly to environmental degradation[31]. The excessive use of fertilizers and pesticides in cultivating plants for PDNP extraction poses a severe threat to the environment. Soil depletion, caused by the overuse of land for specific plant sources, leads to diminished fertility and erosion[32]. Additionally, runoff from these agrochemicals seeps into water bodies, polluting them and disrupting aquatic ecosystems[33]. Furthermore, the extensive monoculture farming practices result in biodiversity loss, as diverse ecosystems are replaced by single-species plantations, disrupting the natural balance and endangering various species[34].

***Nanoparticle Synthesis and Processing:*** The production of PDNPs involves intricate processes of nanoparticle synthesis and subsequent processing, which bring forth their own set of environmental challenges[35].

Nanoparticle synthesis requires energy-intensive procedures, often relying on conventional methods that consume significant amounts of energy. Moreover, many of these processes involve the use of chemicals that may have adverse effects on the environment[36,37]. The reliance on these chemicals raises concerns regarding their ecological impact, especially during manufacturing and synthesis stages. The manufacturing and processing of PDNPs generate considerable waste[38]. From leftover materials and by-products to chemical residues, the waste produced in these processes poses a risk of environmental contamination if not managed and disposed of properly[39]. Improper disposal methods could lead to pollution of soil, water bodies, and even the air, perpetuating environmental hazards[40].

***Disposal and End-of-Life Management:*** Once utilized in medical applications, the fate of PDNPs after their intended use becomes a significant concern. The absence of standardized protocols for the disposal or recycling of PDNPs adds to the environmental quandary[41]. With their unique properties, PDNPs require specific handling and disposal techniques that are yet to be well-defined, potentially leading to their improper disposal, further aggravating environmental risks[42]. The possibility of PDNP residues accumulating in ecosystems and food chains post-use raises alarming ecological concerns[43]. The long-term effects of nanoparticle accumulation on flora, fauna, and ultimately human health remain largely unknown, necessitating rigorous research and responsible waste management practices[44].

Table 1: Types of Plant-Derived Nanoparticles (PDNPs) Used in Cancer Biomarkers

| PDNP Type | Composition | Application in Cancer Biomarkers | Reference |
|---|---|---|---|
| Polysaccharides | Derived from plant polysaccharides | Early detection and targeted therapy for specific cancer types | [45] |
| Proteins | Extracted from plant-based sources | Biomarkers for monitoring treatment responses and disease progression | [46] |
| Lipids | Obtained from plant lipids | Nanocarriers for drug delivery and imaging in cancer diagnostics | [47] |
| Combinations | Mixtures of plant-derived elements | Enhanced specificity in identifying multiple cancer biomarkers | [48] |
| Polysaccharides | Derived from specific plant sources | Targeted imaging and therapy in certain cancer microenvironments | [49] |
| Proteins | Isolated proteins with targeted properties | Development of personalized treatment approaches | [50] |
| Lipids | Lipid-based nanoparticles | Delivery of therapeutics to cancer cells and tissues | [51] |
| Combinations | Mixtures of plant-derived materials | Study of interactions between nanoparticles and cancer cells | [52] |
| Polysaccharides | Natural polymer-based nanoparticles | Evaluating biocompatibility and toxicity profiles | [53] |
| Proteins | Engineered plant protein-based nanocarriers | Targeted drug delivery mechanisms and therapeutic efficacy | [54] |

**Mitigating Environmental Risks: Towards Sustainable PDNPs**

The integration of sustainable practices in the production and utilization of Plant-Derived Nanoparticles (PDNPs) is imperative to mitigate potential environmental repercussions. This section delineates various strategies to address these concerns[55].

***Green Synthesis Methods for PDNP Production:*** The pursuit of eco-friendly approaches in PDNP production involves leveraging plant extracts, enzymes, and microbial processes[56]. These methods harness the inherent capabilities of natural components, fostering a reduction in the ecological footprint associated with

Journal of Chemical Health Risks
www.jchr.org
JCHR (2023) 13(6), 520-529 | ISSN:2251-6727

conventional nanoparticle synthesis[57]. Utilizing plant extracts, particularly phytochemicals and biomolecules, offers a sustainable pathway[58]. These extracts, rich in phytoconstituents like polyphenols or flavonoids, serve as reducing and stabilizing agents in nanoparticle synthesis[59]. Enzymatic routes, employing enzymes derived from plant sources or microorganisms, facilitate precise control over nanoparticle characteristics. This green synthesis paradigm champions not only reduced environmental impact but also engenders PDNPs with inherent biocompatibility and diminished toxicity[60,61].

***Sustainable Agricultural Practices:*** Implementing organic farming methods and embracing water conservation techniques play pivotal roles in fostering sustainable PDNP production. Organic farming circumvents the detrimental effects of agrochemicals, promoting soil health and biodiversity[62]. This shift minimizes the environmental strain stemming from extensive fertilizer and pesticide usage often associated with conventional agricultural practices[63]. Moreover, integrating water conservation strategies within cultivation processes lessens water consumption, thereby mitigating the strain on local water resources. Employing drip irrigation systems, rainwater harvesting, or adopting drought-resistant crop varieties contributes significantly to sustainable PDNP sourcing[64].

***Life Cycle Assessment of PDNP Production and Use:*** A comprehensive life cycle assessment (LCA) is imperative to comprehend the complete environmental footprint of PDNP production and application[65]. This assessment spans from the extraction of raw materials to PDNP synthesis, utilization, and eventual disposal. It encompasses energy consumption, carbon emissions, resource utilization, and waste generation at each stage[66]. Analyzing the environmental impact throughout the lifecycle facilitates informed decision-making. LCA findings aid in identifying hotspots where interventions are most effective. This holistic evaluation paves the way for the development of strategies to minimize adverse environmental consequences associated with PDNP utilization[67,68].

***Development of Biodegradable and Non-Toxic PDNPs:*** Research endeavors focus on engineering PDNPs that are inherently biodegradable and possess minimal toxicity[69]. Exploration into novel materials and synthesis methodologies aims to curtail environmental persistence and adverse effects on ecosystems. By designing PDNPs with innate biodegradability, the risk of long-term environmental accumulation diminishes[70]. Simultaneously, efforts to ensure their non-toxic nature are crucial to prevent ecological disruptions. This approach aligns with the principles of green nanotechnology, advocating for safer and sustainable nanosystems[71].

**Conclusion and Future Perspectives**

As we undertaking deeper into leveraging the capabilities of plant-derived nanoparticles (PDNPs) within the realm of cancer staging and therapy, it becomes increasingly vital to navigate a nuanced equilibrium between their biomedical advantages and the potential environmental repercussions they entail[72]. While PDNPs present enticing prospects for precise cancer diagnosis and targeted therapeutic interventions, the process of their production and utilization necessitates a vigilant evaluation of their ecological implications[73]. This underscores the pivotal need for collaborative efforts encompassing a diverse spectrum of stakeholders to address the ecological consequences associated with PDNP-based technologies. Scientists, engineers, policymakers, and healthcare professionals must unite in a concerted endeavor to guide PDNP research and application towards sustainability[74]. Only through collective action and a shared commitment to responsibility can we pave the way for the conscientious integration of PDNPs in healthcare while safeguarding our environment. Moreover, advancing towards sustainable PDNP technologies requires an ongoing dedication to research and innovation. The pursuit of reducing the environmental footprint attributed to PDNPs mandates continuous exploration into environmentally friendly synthesis methodologies, stringent assessments of their life cycles, and the exploration and development of biodegradable, non-toxic alternatives[75]. Investing in comprehensive studies and establishing robust frameworks will not only enable us to capitalize on the full potential of PDNPs in revolutionizing cancer diagnosis and treatment but also ensure their minimized impact on our fragile ecosystems. This emphasizes the critical importance of simultaneous advancement in biomedical applications and environmental consciousness, steering the trajectory of

PDNP utilization towards a sustainable and responsible future in healthcare[76,77].

**References**

[1] Wang, Z. B.; Jiang, H.; Xia, Y. G.; Yang, B. Y.; Kuang, H. X. α-Glucosidase inhibitory constituents from Acanthopanax senticosus harm leaves. *Molecules* **2012**, *17*(6), 6269–6276. [DOI: 10.3390/molecules17066269]

[2] Chin, W. W.; Parmentier, J.; Widzinski, M.; Tan, E. H.; Gokhale, R. A brief literature and patent review of nanosuspensions to a final drug product. *J. Pharm. Sci.* **2014**, *103*(10), 2980–2999. [DOI: 10.1002/jps.24098]

[3] Hwang, K. A.; Park, M. A.; Kang, N. H.; Yi, B. R.; Hyun, S. H.; Jeung, E. B.; Choi, K. C. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β- estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor alpha and insulin-like growth factor-1 receptor signaling pathways. *Toxicol. Appl. Pharmacol.* **2013**, *272*(3), 637–646.

[4] Choi, E. J.; Jung, J. Y.; Kim, G. H. Genistein inhibits the proliferation and differentiation of MCF-7 and 3T3-L1 cells via the regulation of ERα expression and induction of apoptosis. *Exp. Ther. Med.* **2014**, *8*(2), 454–458.

[5] Luo, Y.; Wang, S. X.; Zhou, Z. Q.; Wang, Z.; Zhang, Y. G.; Zhang, Y.; Zhao, P. Apoptotic effect of genistein on human colon cancer cells via inhibiting the nuclear factor- kappa B (NF-κB) pathway. *Tumour Biol.* **2014**, *35*(11), 11483–11488.

[6] Yamasaki, M.; Mine, Y.; Nishimura, M.; Fujita, S.; Sakakibara, Y.; Suiko, M.; Morishita, K.; Nishiyama, K. Genistein induces apoptotic cell death associated with inhibition of the NF-κB pathway in adult T-cell leukaemia cells. *Cell Bio Int.* **2013**, *37*(7), 742–747. [DOI: 10.1002/cbin.10101]

[7] Zhang, Z.; Wang, C. Z.; Du, G. J.; Qi, L. W.; Calway, T.; He, T. C. et al. Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. *Int. J. Oncol.* **2013**, *43*(1), 289–296.

[8] Hirata, H.; Hinoda, Y.; Shahryari, V.; Deng, G.; Tanaka, Y.; Tabatabai, Z. L.; Dahiya, R. Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. *Br. J. Cancer* **2014**, *110*(6), 1645–1654.

[9] Hirata, H.; Ueno, K.; Nakajima, K.; Tabatabai, Z. L.; Hinoda, Y.; Ishii, N.; Dahiya, R. Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. *Br. J. Cancer* **2013**, *108*(10), 2070–2078.

[10] Chiyomaru, T.; Yamamura, S.; Fukuhara, S.; Hidaka, H.; Majid, S.; Saini, S. et al. Genistein up-regulates tumour suppressor microRNA-574-3p in prostate cancer. *PLoS One* **2013**, *8*(3), e58929.

[11] Trejo-Solís, C.; Pedraza-Chaverrí, J.; Torres-Ramos, M.; Jiménez-Farfán, D.; Cruz Salgado, A.; Serrano-García, N. et al. Multiple molecular and cellular mechanisms of action of lycopene in cancer inhibition. *Evid Based Complement Altern Med* **2013**, *2013*, 705121. [DOI: 10.1155/2013/705121]

[12] Uppala, P. T.; Dissmore, T.; Lau, B. H.; Andacht, T.; Rajaram, S. Selective inhibition of cell proliferation by lycopene in MCF-7 breast cancer cells in vitro: a proteomic analysis. *Phytother Res.* **2013**, *27*(4), 595–601. [DOI: 10.1002/ptr.4764]

[13] Gharib, A.; Faezizadeh, Z. In vitro anti-telomerase activity of novel lycopene-loaded nanospheres in the human leukaemia cell line K562. *Pharmacogn Mag.* **2014**, *10*(Suppl 1), S157.

[14] Haddad, N. F.; Teodoro, A. J.; Leite de Oliveira, F.; Soares, N.; de Mattos, R. M.; Hecht, F. et al. Lycopene and beta-carotene induce growth inhibition and proapoptotic effects on ACTH-secreting pituitary adenoma cells. *PLoS One* **2013**, *8*(5), e62773.

[15] Elgass, S.; Cooper, A.; Chopra, M. Lycopene treatment of prostate cancer cell lines inhibits adhesion and migration properties of the cells. *Int. J. Med. Sci.* **2014**, *11*(9), 948.

[16] Holzapfel, N. P.; Holzapfel, B. M.; Champ, S.; Feldthusen, J.; Clements, J.; Hutmacher, D. W. The potential role of lycopene for the

prevention and therapy of prostate cancer: from molecular mechanisms to clinical evidence. *Int. J. Mol. Sci.* **2013**, *14*(7), 14620–14646. [DOI: 10.3390/ijms140714620]

[17] Yang, C. M.; Yen, Y. T.; Huang, C. S.; Hu, M. L. Growth inhibitory efficacy of lycopene and β-carotene against androgen-independent prostate tumor cells xenografted in nude mice. *Mol. Nutr. Food Res.* **2011**, *55*(4), 606–612.

[18] Chari, R. V.; Miller, M. L.; Widdison, W. C. Antibody–drug conjugates: an emerging concept in cancer therapy. *Angew Chem Int Ed* **2014**, *53*(15), 3796–3827.

[19] Maeda, H.; Nakamura, H.; Fang, J. The EPR effect for macromolecular drug delivery to solid tumours: improvement of tumour uptake, lowering of systemic toxicity, and distinct tumour imaging in vivo. *Adv. Drug Deliv. Rev.* **2013**, *65*(1), 71–79.

[20] Fang, J.; Nakamura, H.; Maeda, H. The EPR effect: unique features of tumour blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. *Adv. Drug Deliv. Rev.* **2011**, *63*(3), 136–151.

[21] Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Adv. Drug Deliv. Rev.* **2014**, *66*, 2–25.

[22] Patel, N. R.; Pattni, B. S.; Abouzeid, A. H.; Torchilin, V. P. Nanopreparations to overcome multidrug resistance in cancer. *Adv. Drug Deliv. Rev.* **2013**, *65*(13–14), 1748–1762.

[23] Alexis, F.; Rhee, J. W.; Richie, J. P.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. New frontiers in nanotechnology for cancer treatment. In: *Urologic Oncology: Seminars and Original Investigations*, 26(1), 74–85.

[24] Liang, Y.; Li, Y.; Wang, H.; Zhou, J.; Wang, J.; Regier, T.; Dai, H. Co3O4 nanocrystals on graphene as a synergistic catalyst for oxygen reduction reaction. *Nat. Mater.* **2011**, *10*(10), 780–786.

[25] Stinchcombe, T. E. Nanoparticle albumin-bound paclitaxel: a novel Cremphor- EL®-free formulation of paclitaxel. *Nanomedicine* **2007**, *2*(4), 415.

[26] Miele, E.; Spinelli, G. P.; Miele, E.; Tomao, F.; Tomao, S. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. *Int. J. Nanomedicine* **2009**, *4*, 99.

[27] Singh, K.; Sai Nandhini, R.; Palanivelu, J. Nanosponges: in perspective to therapeutic medicine. In: *Nanotechnology in Medicine*. Springer, Cham, pp 87–104.

[28] Kratz, F.; Elsadek, B. Clinical impact of serum proteins on drug delivery. *J. Control Release* **2012**, *161*(2), 429–445.

[29] Petrelli, F.; Borgonovo, K.; Barni, S. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel. *Expert Opin. Pharmacother.* **2010**, *11*(8), 1413–1432.

[30] Reddy, L. H.; Bazile, D. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics. *Adv. Drug Deliv. Rev.* **2014**, *71*, 34–57.

[31] Jiao, H.; Barakat, N. Balanced depth and breadth in a new interdisciplinary nanotechnology course. J. Educ. Technol. Syst. 2012, 40 (1), 75–87.

[32] Khan, I.; Saeed, K.; Khan, I. Nanoparticles: properties, applications and toxicities. Arab J. Chem. 2017, 12 (7), 908–31.

[33] Som, C.; Wick, P.; Krug, H.; Nowack, B. Environmental and health effects of nanomaterials in nanotextiles and facade coatings. Environ. Int. 2011, 37, 1131–42.

[34] Bottero, J. Y.; Rose, J.; Wiesner, M. R. Nanotechnologies: Tools for sustainability in a new wave of water treatment processes. Integr. Environ. Assess. Manag. 2006, 2, 391–5.

[35] Pak, T.; Archilha, N. L.; de Lima Luz, L. F. Nanotechnology-Based Remediation of Groundwater. In Nanotechnology Characterization Tools for Environment, Health, and Safety; Kumar, C., Ed.; Springer: Berlin, Heidelberg, 2019; pp. 145–65.

[36] Pak, T.; Archilha, N. L.; Al-Imari, R. Application of nanotechnology in removal of

NAPLs from contaminated aquifers: a source clean-up experimental study. Clean Technol. Environ. Policy 2018, 20, 427–33.
[37] Pak, T.; Luz, L. F. D. L.; Tosco, T.; Costa, G. S. R.; Rosa, P. R. R.; Archilha, N. L. Pore-scale investigation of the use of reactive nanoparticles for in situ remediation of contaminated groundwater source. Proc. Natl. Acad. Sci. U.S.A. 2020, 117 (24), 13366–73.
[38] Lammers, T.; Hennink, W. E.; Storm, G. Tumour-targeted nanomedicines: Principles and practice. Br. J. Cancer 2008, 99, 392–7.
[39] Gupta, A. K.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2006, 26, 3995–4021.
[40] Botta, C.; Labille, J.; Auffan, M.; Borschneck, D.; Miche, H.; Cabie, M., et al. TiO2-based nanoparticles released in water from commercialized sunscreens in a life-cycle perspective: structures and quantities. Environ. Pollut. 2011, 159, 1543–50.
[41] Auffan, M.; Bottero, J. Y.; Chaneac, C.; Rose, J. Inorganic manufactured nanoparticles: How their physicochemical properties influence their biological effects in aqueous environments. Nanomed. Nanotechnol. Biol. Med. 2010, 5, 999–1007.
[42] Oberdorster, G.; Oberdorster, E.; Oberdorster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113, 823–39.
[43] Magrez, A.; Kasas, S.; Salicio, V.; Pasquier, N.; Seo, J. W.; Celio, M., et al. Cellular toxicity of carbon-based nanomaterials. Nano Lett. 2006, 6 (6), 1121–5.
[44] Mancuso, L.; Cao, G. Acute toxicity test of CuO nanoparticles using human mesenchymal stem cells. Toxicol. Mech. Methods 2014, 24 (7), 449–54.
[45] Yokel, R. A.; MacPhail, R. C. Engineered nanomaterials: exposures, hazards, and risk prevention. J. Occup. Med. Toxicol. 2011, 6, 7.
[46] Jeevanandam, J.; Barhoum, A.; Chan, Y. S.; Dufresne, A.; Danquah, M. K. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulation. Beilstein J. Nanotechnol. 2018, 9, 908–31.
[47] Sahu, S. C.; Hayes, A. W. Toxicity of nanomaterials found in human environment: a literature review. Toxicol. Res. Appl. 2017, 1, 2397847317726352.
[48] Aromataris, E.; Munn, Z. (Editors). JBI Manual for Evidence Synthesis. Joanna Briggs Institute. 2020. Available from: https://doi.org/10.46658/JBIMES-20-01
[49] Kumah, E. A.; Zohoori, V.; Pak, T.; Harati, S.; Raoul, F. D.; Boadu, P. Effects of nanotechnology: A scoping review of the current literature. OSF; 2021. Available from: osf.io/w67m9.
[50] Boczkowski, J.; Hoet, P. What's new in nanotechnology? Implications for public health from a brief review of the 2008 literature. Nanotoxicology 2010, 4 (1), 1–14.
[51] Phuyal, S.; Kasem, M.; Rubio, L.; Karlsson, H. L.; Marcos, R.; Skaug, V., et al. Effects on human bronchial epithelial cells following low-dose chronic exposure to nanomaterials: A 6-month transformation study. Toxicol Vitro : Int. J. Publishe Assoc. BIBRA 2017, 44, 230–40.
[52] Shalini, D.; Senthilkumar, S.; Rajaguru, P. Effect of size and shape on toxicity of zinc oxide (ZnO) nanomaterials in human peripheral blood lymphocytes. Toxicol. Mech. Methods 2018, 28 (2), 87–94.
[53] Sharma, S. K.; Bhatt, P.; Asdaq, S. M. B.; Alshammari, M. K.; Alanazi, A.; Alrasheedi, N. S.; Alrashdi, B. A.; Alyami, S. S.; Alhazmi, B. H.; Alam, P.; Sharma, P.; Tomar, R.; Arora, M. K.; Imran, M. Combined Therapy with Ivermectin and Doxycycline Can Effectively Alleviate the Cytokine Storm of COVID-19 Infection amid Vaccination Drive: A Narrative Review. J. Infect. Public Health 2022, 15 (5), 566–572. https://doi.org/10.1016/j.jiph.2022.03.014.
[54] Chand, S. P.; Debnath, S.; Rahimi, M.; Ashraf, M. S.; Bhatt, P.; Rahin, S. A. Contextualization of Trait Nexus and Gene Action for Quantitative and Qualitative Characteristics in Indian Mustard. J. Food Qual. 2022, 2022, 1–24. https://doi.org/10.1155/2022/4387318.
[55] Singh, S.; Pankaj, B.; Nagarajan, K.; P. Singh, N.; Bala, V. Blockchain with Cloud for Handling Healthcare Data: A Privacy-Friendly

Platform. Mater. Today 2022, 62, 5021–5026. https://doi.org/10.1016/j.matpr.2022.04.910.

[56] Ahamed, S.; Bhatt, P.; Sultanuddin, S. J.; Walia, R.; Haque, M. A.; InayathAhamed, S. B. An Intelligent IoT Enabled Health Care Surveillance Using Machine Learning. In 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI); IEEE, 2022.

[57] Bhatt, P.; Kumar, V.; Goel, R.; Sharma, S. K.; Kaushik, S.; Sharma, S.; Shrivastava, A.; Tesema, M. Structural Modifications and Strategies for Native Starch for Applications in Advanced Drug Delivery. Biomed Res. Int. 2022, 2022, 1–14. https://doi.org/10.1155/2022/2188940.

[58] Bhatt, P.; Singh, S.; Kumar Sharma, S.; Rabiu, S. Development and Characterization of Fast Dissolving Buccal Strip of Frovatriptan Succinate Monoydrate for Buccal Delivery. Int. J. Pharm. Investig. 2021, 11 (1), 69–75. https://doi.org/10.5530/ijpi.2021.1.13.

[59] Al-Snafi, A. E.; Singh, S.; Bhatt, P.; Kumar, V. A Review on Prescription and Non-Prescription Appetite Suppressants and Evidence-Based Method to Treat Overweight and Obesity. GSC biol. pharm. sci. 2022, 19 (3), 148–155. https://doi.org/10.30574/gscbps.2022.19.3.0231.

[60] Singh, S.; Bhatt, P.; Alfuraiji, N.; Thuwaini, M. M.; Snafi, A. E. Cardiovascular Comorbidity of COVID-19 Disease: A Review. WJPMR 2022, 8 (4), 216–225.

[61] Malik, M. K.; Bhatt, P.; Kumar, T.; Singh, J.; Kumar, V.; Faruk, A.; Fuloria, S.; Fuloria, N. K.; Subrimanyan, V.; Kumar, S. Significance of Chemically Derivatized Starch as Drug Carrier in Developing Novel Drug Delivery Devices. Nat. Prod. J. 2022, 12. https://doi.org/10.2174/2210315512666220819112334.

[62] Pankaj. Anti-Cancer Cyclodextrin Nanocapsules Based Formulation Development for Lung Chemotherapy. J. Pharm. Res. Int. 2021, 54–63. https://doi.org/10.9734/jpri/2020/v32i3931024.

[63] Pankaj. Cyclodextrin Modified Block Polymer for Oral Chemotherapy. J. Pharm. Res. Int. 2021, 21–29. https://doi.org/10.9734/jpri/2020/v32i3831009.

[64] Singh, S.; Kumar Sharma, S.; Mehrotra, P.; Bhatt, P.; Kaurav, M. Blockchain Technology for Efficient Data Management in Healthcare System: Opportunity, Challenges and Future Perspectives. Mater. Today 2022, 62, 5042–5046. https://doi.org/10.1016/j.matpr.2022.04.998.

[65] Malik, M. K.; Bhatt, P.; Singh, J.; Kaushik, R. D.; Sharma, G.; Kumar, V. Preclinical Safety Assessment of Chemically Cross-Linked Modified Mandua Starch: Acute and Sub-Acute Oral Toxicity Studies in Swiss Albino Mice. ACS Omega 2022, 7 (40), 35506–35514. https://doi.org/10.1021/acsomega.2c01309.

[66] Kaur, T.; Singh, S. Controlled Release of Bi-Layered Malvidin Tablets Using 3D Printing Techniques. J. Pharm. Res. Int. 2021, 70–78. https://doi.org/10.9734/jpri/2020/v32i4031034.

[67] Bhatt, P.; Singh, S.; Sharma, S. K.; Kumar, V. Blockchain Technology Applications for Improving Quality of Electronic Healthcare System. In Blockchain for Healthcare Systems; CRC Press: Boca Raton, 2021; pp 97–113.

[68] Singh, S.; Bhatt, P.; Sharma, S. K.; Rabiu, S. Digital Transformation in Healthcare: Innovation and Technologies. In Blockchain for Healthcare Systems; CRC Press: Boca Raton, 2021; pp 61–79.

[69] Malik, M. K.; Kumar, V.; Singh, J.; Bhatt, P.; Dixit, R.; Kumar, S. Phosphorylation of Alkali Extracted Mandua Starch by STPP/STMP for Improving Digestion Resistibility. ACS Omega 2023, 8 (13), 11750–11767. https://doi.org/10.1021/acsomega.2c05783.

[70] Bhatt, P.; Kumar, A.; Shukla, R. Nanorobots Recent and Future Advances in Cancer or Dentistry Therapy- A Review. Am. J. PharmTech Res. 2019, 9 (3), 321–331. https://doi.org/10.46624/ajptr.2019.v9.i3.027.

[71] Sharma, S. K.; Bhatt, P. Controlled Release of Bi-Layered EGCG Tablets Using 3D Printing Techniques. J. Pharm. Res. Int. 2021, 5–13. https://doi.org/10.9734/jpri/2020/v32i3931019.

[72] Kumar, A.; Bhatt, P.; Mishra, N. Irritable Bowel Syndrome with Reference of Alosetron Hydrochloride and Excipient Profile Used in the

Manufacturing of Alosetron Tablet-A Review. J. Chem. Pharm. Sci. 2019, 12 (03), 71–78. https://doi.org/10.30558/jchps.20191203002.

[73] Bhatt, P.; Kumar, V.; Subramaniyan, V.; Nagarajan, K.; Sekar, M.; Chinni, S. V.; Ramachawolran, G. Plasma Modification Techniques for Natural Polymer-Based Drug Delivery Systems. Pharmaceutics 2023, 15 (8). https://doi.org/10.3390/pharmaceutics15082066.

[74] Bhatt, P.; Kumar, V.; Rastogi, H.; Malik, M. K.; Dixit, R.; Garg, S.; Kapoor, G.; Singh, S. Functional and Tableting Properties of Alkali-Isolated and Phosphorylated Barnyard Millet (Echinochloa Esculenta) Starch. ACS Omega 2023, 8 (33), 30294–30305. https://doi.org/10.1021/acsomega.3c03158.

[75] Encyclopedia of Green Materials; Baskar, C., Ramakrishna, S., Daniela La Rosa, A., Eds.; Springer Nature Singapore: Singapore, 2022.

[76] Bhatt, P.; Singh, S.; Kumar, V.; Nagarajan, K.; Mishra, S. K.; Kumar Dixit, P.; Kumar, V.; Kumar, S. Artificial Intelligence in Pharmaceutical Industry: Revolutionizing Drug Development and Delivery. The Chinese Journal of Artificial Intelligence 2023, 02. https://doi.org/10.2174/0129503752250813231124092946.

[77] Sahu, K. K.; Kaurav, M.; Bhatt, P.; Minz, S.; Pradhan, M.; Khan, J.; Sahu, R. K.; Yadav, K. Utility of Nanomaterials in Wound Management. In Nanotechnological Aspects for Next-Generation Wound Management; Elsevier, 2024; pp 101–130.